{
    "clinical_study": {
        "@rank": "124571", 
        "arm_group": {
            "arm_group_label": "Diagnostic (F-18 FES PET)", 
            "arm_group_type": "Experimental", 
            "description": "Patients undergo F-18 FES PET scan at baseline. Patients also undergo F-18 FES PET and FDG PET between 1-12 weeks after starting therapy, and then 1-12 weeks after the second FES PET scan."
        }, 
        "brief_summary": {
            "textblock": "This clinical trial studies F-18 16 alpha-fluoroestradiol (F-18 FES) positron emission\n      tomography (PET) in measuring hormone expression in patients with recurrent or metastatic\n      breast cancer undergoing endocrine-targeted therapy. Comparing results of diagnostic\n      procedures done before, during, and after hormone therapy may help measure a patient's\n      response to treatment."
        }, 
        "brief_title": "F-18 FES PET in Measuring Hormone Expression in Patients With Recurrent or Metastatic Breast Cancer Undergoing Endocrine-Targeted Therapy", 
        "condition": [
            "Estrogen Receptor-positive Breast Cancer", 
            "Recurrent Breast Cancer", 
            "Stage IV Breast Cancer"
        ], 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. Measure the effect of endocrine targeted therapy on estrogen receptor (ER) expression and\n      estradiol binding to the receptor using serial FES PET and fludeoxyglucose (FDG) PET.\n\n      SECONDARY OBJECTIVES:\n\n      I. Document the safety profile of FES PET in patients with breast cancer.\n\n      II. Examine associations between FES PET results and serial measurements of hormone or other\n      levels in peripheral blood, as related to efficacy of endocrine-targeted therapy. Correlate\n      FES PET uptake measures with pathology tissue assays if relevant to specific treatment\n      regimen.\n\n      OUTLINE:\n\n      Patients undergo F-18 FES PET scan at baseline. Patients also undergo F-18 FES PET and FDG\n      PET between 1-12 weeks after starting therapy, and then 1-12 weeks after the second FES PET\n      scan.\n\n      After completion of study treatment, patients are followed for up to 20 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult, non-pregnant patients with biopsy-proven or clinically obvious primary,\n             recurrent or metastatic breast cancer\n\n          -  Breast cancer from ER+ primary that is seen on other imaging tests; tumor ER\n             expression must have been confirmed by immunohistocytochemistry of primary tumor or\n             recurrent disease\n\n          -  At least one site of disease 1.5 cm or greater is needed to meet the spatial\n             resolution limits of PET imaging\n\n          -  Patients must have been off tamoxifen or other estrogen receptor blocking agents for\n             at least 6 weeks and off chemotherapy for 3 weeks for the initial baseline FES\n\n          -  Patients must be selected for an endocrine targeted therapy regimen for treatment of\n             their breast cancer by the referring oncologist; selected treatments may be part of\n             experimental treatment protocols for which the patient would be separately consented\n\n          -  Patients must be willing to undergo serial imaging procedures\n\n          -  Patients must agree to allow access to clinical records regarding response to\n             treatment and long term follow up\n\n        Exclusion Criteria:\n\n          -  An inability to lie still for the tests\n\n          -  Individuals weighing more than 300 lb; (this is the weight limit of the scanner\n             table)\n\n          -  Pregnant or lactating; women of childbearing potential with either a positive or no\n             pregnancy test at baseline are excluded\n\n          -  Any other life-threatening illness (e.g. serious, uncontrolled concurrent infection\n             or clinically significant cardiac disease - congestive heart failure, symptomatic\n             coronary artery disease, cardiac arrhythmia not well controlled with medication)\n\n          -  Use of tamoxifen, Faslodex, diethylstilbestrol (DES) or any other ER blocking agent <\n             6 weeks or chemotherapy < 3 weeks prior to imaging scan\n\n          -  Unwillingness or inability to give informed consent\n\n          -  Uncontrolled diabetes mellitus (fasting glucose > 200 mg/dL)\n\n          -  Adult patients who require monitored anesthesia for PET scanning"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 1, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02149173", 
            "org_study_id": "7184", 
            "secondary_id": [
                "NCI-2013-02342", 
                "7184", 
                "P30CA015704", 
                "P01CA042045"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Diagnostic (F-18 FES PET)", 
                "description": "Undergo F-18 FES PET", 
                "intervention_name": "F-18 16 alpha-fluoroestradiol", 
                "intervention_type": "Radiation", 
                "other_name": [
                    "F-18 FES", 
                    "fluorine-18 16 alpha-fluoroestradiol"
                ]
            }, 
            {
                "arm_group_label": "Diagnostic (F-18 FES PET)", 
                "description": "Undergo F-18 FES PET", 
                "intervention_name": "positron emission tomography", 
                "intervention_type": "Procedure", 
                "other_name": [
                    "FDG-PET", 
                    "PET", 
                    "PET scan", 
                    "tomography, emission computed"
                ]
            }, 
            {
                "arm_group_label": "Diagnostic (F-18 FES PET)", 
                "description": "Undergo FDG PET", 
                "intervention_name": "fludeoxyglucose F 18", 
                "intervention_type": "Radiation", 
                "other_name": [
                    "18FDG", 
                    "FDG"
                ]
            }, 
            {
                "arm_group_label": "Diagnostic (F-18 FES PET)", 
                "description": "Undergo FDG PET", 
                "intervention_name": "positron emission tomography", 
                "intervention_type": "Procedure", 
                "other_name": [
                    "FDG-PET", 
                    "PET", 
                    "PET scan", 
                    "tomography, emission computed"
                ]
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 23, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Janet F. Eary", 
                    "phone": "205-934-3138"
                }, 
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35294"
                    }, 
                    "name": "University of Alabama Comprehensive Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Janet F. Eary", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "David A. Mankoff", 
                    "phone": "215-615-3687"
                }, 
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19104"
                    }, 
                    "name": "University of Pennsylvania/Abramson Cancer Center"
                }, 
                "investigator": {
                    "last_name": "David A. Mankoff", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Hannah M. Linden", 
                    "phone": "206-288-6710"
                }, 
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98109"
                    }, 
                    "name": "Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium"
                }, 
                "investigator": {
                    "last_name": "Hannah M. Linden", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Serial [F-18] Fluoroestradiol (FES) PET Imaging to Evaluate Endocrine-Targeted Therapy", 
        "overall_official": {
            "affiliation": "Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium", 
            "last_name": "Hannah Linden", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Quantitative and qualitative measures of FES update for each disease site, a set of 1.5 cm diameter regions on three adjacent planes with the highest lesion FES uptake will be drawn to determine maximal FES uptake. Up to the largest 3 lesions seen on the dynamic scan will be quantified, and up to the 5 largest sites seen on the static torso survey will be quantified. Partial-volume correction will not be used because only sites 1.5 cm or greater diameter will be included in quantitative analysis.", 
                "measure": "FES uptake", 
                "safety_issue": "No", 
                "time_frame": "Up to 20 years"
            }, 
            {
                "measure": "Change in FES standardized uptake value (SUV), assessed by a one-sample test of the percent change in FES SUV", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 20 years"
            }, 
            {
                "description": "Reported using a 90% Wilson score binomial confidence interval.", 
                "measure": "Proportion of patients experienced a threshold in percentage change, or surpassed a targeted follow-up FES SUV value", 
                "safety_issue": "No", 
                "time_frame": "Up to 20 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02149173"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Time to disease progression", 
                "safety_issue": "No", 
                "time_frame": "From the start of endocrine therapy to the time the patient is first recorded as having disease progression, assessed up to 20 years"
            }, 
            {
                "description": "Estrogen receptor is examined in descriptive analyses.", 
                "measure": "Expression of biologic correlates", 
                "safety_issue": "No", 
                "time_frame": "Up to 20 years"
            }, 
            {
                "description": "Progesterone receptor is examined in descriptive analyses.", 
                "measure": "Expression of biologic correlates", 
                "safety_issue": "No", 
                "time_frame": "Up to 20 years"
            }, 
            {
                "description": "Human epidermal growth factor receptor is examined in descriptive analyses.", 
                "measure": "Expression of biologic correlates", 
                "safety_issue": "No", 
                "time_frame": "Up to 20 years"
            }
        ], 
        "source": "University of Washington", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "University of Washington", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2010", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}